METiS TechBio, a Hong Kong-based startup, is revolutionizing drug delivery using AI technology, evidenced by a remarkable 173% surge in its stock price during its debut. This strong market response highlights the growing investor interest in AI-driven healthcare innovations.
The company, which focuses on AI-enhanced drug design, priced its initial public offering at HK$10.50 per share, but it opened at HK$28.68, reflecting high demand. Co-founder and CEO Lai Tsai-Ta emphasized that their AI algorithms significantly accelerate drug development timelines, reducing them from years to just 18 months.
METiS TechBio specializes in creating "nano-rockets" that can transport pharmaceutical compounds via nanodelivery systems. This innovative approach allows pharmaceutical companies to integrate their drugs into these nano-rockets, potentially transforming how medications are delivered to patients.
Having raised HK$2.11 billion (approximately US$269.5 million) from the IPO, METiS TechBio joins the ranks of other AI-focused drug developers that have recently gone public in Hong Kong. The enthusiastic reception of its shares reflects a broader trend where AI-related stocks are gaining traction, particularly as Chinese tech firms increasingly seek to list on the Hong Kong exchange. This trend underscores the market's optimism about the intersection of AI and life sciences.